Offloading Biosimilars To Biocon ‘First Step’ Towards Viatris’ $9bn Target
Viatris On ‘Clear Path’ To Building In Generics And Complex Generics
Executive Summary
After confirming rumors that it would offload its biosimilars unit to its long-term partner Biocon, Viatris has outlined plans to add to the expected cash proceeds with other divestments to complete on several strategic goals up to 2023. Bumping up R&D spending to facilitate complex generic launches is a continued priority for the company.